Document:

Execution Copy

 

AMENDMENT NO. 1
TO RESEARCH AND LICENSE AGREEMENT

 

This
Amendment No. 1 (“Amendment”), effective as of March 9, 2011 (“Amendment Effective Date”),
is made by and between

 

Debiopharm
S.A., a stock company duly established under the laws of Switzerland, with registered company number CH-550-0173350-8,
whose registered office is at Forum “après-demain”, Chemin Messidor 5-7,1006 Lausanne, Switzerland
(“DEBIOPHARM”),

 

And

 

Marina
Biotech, Inc., a company duly established under the laws of the State of Delaware, whose registered office is at 3830 Monte
Villa Parkway, Bothell, Washington 98021, U.S.A. (“COMPANY”),

 

WITNESSETH:

 

Whereas,
DEBIOPHARM and COMPANY are parties to that certain Research and License Agreement with an effective date of February 3, 2011 (the
“Agreement”); and

 

Whereas,
the Parties desire to amend the Agreement as set forth herein;

 

Now,
therefore, the Parties hereby agree as follows:

 

		1.	Unless otherwise defined herein, capitalized terms used in this Amendment shall have the meanings assigned thereto in the Agreement.

 

		2.	Section 10.1.1 shall be amended to add the following new subsection (f):

 

		(f)	PLK-1 and/or survivin siRNA may be used by COMPANY in performance of the Joint Research Plan in in vivo and/or in
vitro models as positive test controls. For the avoidance of doubt, any Intellectual Property generated by COMPANY specifically
and exclusively on PLK-1 and/or survivin shall be solely owned by COMPANY and are not included in the Licensed Rights.

 

		3.	Article 12 shall be amended to add the following new Section 12.8:

 

		12.8	Survival. Termination of this Agreement will not affect the rights and obligations of the Parties
accrued under this Agreement prior to termination. Sections 10.1, 19.10, 19.11, 19.12, 19.14 and 19.15, and Articles 12, 14, 15,
16, 17 and 18 shall survive expiration or early termination of this Agreement, together with any provisions which by their purpose
have a term beyond the termination of this Agreement.

 

		4.	Section 15.1 shall be amended and replaced in its entirety with the following:

 

		15.1	The Receiving Party agrees to keep confidential Confidential
                                                                Information disclosed to it by the Disclosing Party, not to disclose
                                                                the Confidential Information to any Third Party unless it first
                                                                obtains the written consent of the Disclosing Party and not to
                                                                use the Confidential Information other than as permitted by the
                                                                terms of this Agreement. DEBIOPHARM may disclose Confidential
                                                                Information, without COMPANY’S prior written consent, to
                                                                its consultants, experts, (potential) subcontractors and manufacturers
                                                                and business partners who have a legitimate need to have access
                                                                to said Confidential Information, who shall be bound by confidentiality
                                                                and non-use commitments no less restrictive than those of this
                                                                Agreement, and who shall have been made aware of the confidential
                                                                nature of the Confidential Information. For the avoidance of doubt,
                                                                any data, including Data, developed by COMPANY prior to the Effective
                                                                Date of the Agreement and which have been the object of (a) presentation(s)
                                                                to third parties without obligations of confidentiality or otherwise
                                                                published by COMPANY may be disclosed by COMPANY without DEBIOPHARM’s
                                                                prior w consent.

  

	CONFIDENTIAL	Amendment No. 1 –  Research and License Agreement	Page 1 of 2
	 	 	 

 

    	 

    	 

    

 

Execution Copy

 

		5.	Except as amended herein, all other terms and conditions of the Agreement shall remain in
                                                           full force and effect.

 

		6.	This Amendment may be executed in counterparts, each of which shall be deemed an original
                                                           and                                                            all of which together shall constitute one and the same
                                                           instrument. Any signature page delivered by facsimile or electronic image
                                                           transmission shall be binding to the same extent as an original signature page.

 

In
witness whereof, the Parties hereby accept and agree to the terms and conditions of the Amendment as of the Amendment Effective
Date.

  

	DEBIOPHARM S.A.	 	MARINA BIOTECH, INC.
	 	 	 	 	 
	By:	/s/ Dr R.Y. Mauvernay	 	By:	/s/ J. MICHAEL FRENCH
	 	 	 	 	 
	Name:	Dr R.Y. Mauvernay	 	Name:	J. MICHAEL FRENCH
	 	 	 	 	 
	Title:	President	 	Title:	President & CEO

 

 

 

	CONFIDENTIAL	Amendment No. 1 –  Research and License Agreement	Page 2 of 2EXECUTION COPY

 

AMENDMENT NO. 2 TO RESEARCH AND LICENSE
AGREEMENT

 

This
Amendment No. 2 (“Amendment 2”), effective as of April 1, 2011 (“Amendment 2 Effective
Date”), is made by and between

 

Debiopharm
S.A., a stock company duly established under the laws of Switzerland, with registered company number CH-550-0173350-8,
whose registered office is at Forum “après-demain”, Chemin Messidor 5-7, 1006 Lausanne, Switzerland
(“DEBIOPHARM”),

 

And

 

Marina
Biotech, Inc., a company duly established under the laws of the State of Delaware, whose registered office is at 3830 Monte
Villa Parkway, Bothell, Washington 98021, U.S.A. (“COMPANY”),

 

WITNESSETH:

 

Whereas, DEBIOPHARM
and COMPANY are parties to that certain Research and License Agreement with an effective date of February 3, 2011, as amended
by Amendment No. 1 with an effective date of March 9, 2011 (collectively, the “Agreement”); and

 

Whereas,
the Parties desire to amend the Agreement as set forth herein;

 

Now,
therefore, the Parties hereby agree as follows:

 

		1.	Unless otherwise defined herein, capitalized terms used in this Amendment shall have the meanings assigned thereto in the Agreement.

 

		2.	The definition of “Collaboration Targets” set forth in Section 1.1 shall be amended to read as follows:

 

“Collaboration Targets” means the
target genes identified in Exhibit 1-1 plus an additional target selected by
DEBIOPHARM                                                                                     by May 3, 2011.

 

		3.	Exhibit 1 shall be amended and replaced in its entirety with Exhibit 1-1, attached hereto and incorporated herein
by this reference

 

		4.	Except as amended herein, all other terms and conditions of the Agreement shall remain in full force and effect.

 

		5.	This Amendment 2 may be executed in counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding
to the same extent as an original signature page.

 

[Signature page follows]

 

 

    	CONFIDENTIAL	Amendment No. 2 – Research and License Agreement	 

    	 

    

 

EXECUTION COPY

 

In
witness whereof, the Parties hereby accept and agree to the terms and conditions of this Amendment as of the Amendment 2
Effective Date.

 

	DEBIOPHARM S.A.	 	MARINA BIOTECH, INC.
	 	 	 
	By:	/s/ R.Y.  Mauvernay	 	By:	/s/ J. MICHAEL FRENCH
	 	 	 	 	 
	Name:	R.Y. Mauvernay	 	Name:	J. MICHAEL FRENCH
	 	 	 	 	 
	Title:	 	 	Title:	PRESIDENT & CEO

 

 

    	CONFIDENTIAL	Amendment No. 2 – Research and License AgreementAMENDMENT NO. 3 TO RESEARCH AND LICENSE
AGREEMENT

 

This
Amendment No. 3 (“Amendment 3”), effective as of May 10, 2011 (“Amendment 3 Effective
Date”), is made by and between

 

Debiopharm
S.A., a stock company duly established under the laws of Switzerland, with
registered company number CH-550-0173350-8, whose registered office is at Forum “après-demain”, Chemin
Messidor 5-7, 1006 Lausanne, Switzerland (“DEBIOPHARM”),

 

And

 

Marina
Biotech, Inc., a company duly established under the laws of the State of Delaware, whose registered office is at 3830 Monte
Villa Parkway, Bothell, Washington 98021, U.S.A. (“COMPANY”),

 

WITNESSETH:

 

Whereas, DEBIOPHARM
and COMPANY are parties to that certain Research and License Agreement with an effective date of February 3, 2011, as amended
by Amendment No. 1 with an effective date of March 9, 2011, and Amendment No. 2 with an effective date of April 1, 2011 (collectively,
the “Agreement”); and

 

Whereas, the Parties
desire to amend the Agreement as set forth herein;

 

Now, therefore,
the Parties hereby agree as follows:

 

		1.	Unless otherwise defined herein, capitalized terms used in this Amendment shall have the meanings assigned thereto in the Agreement.

 

		2.	The definition of “Collaboration Targets” set forth in Section 1.1 shall be amended to read as follows:

 

“Collaboration Targets” means
the target genes identified in Exhibit 1-2.

 

		3.	Exhibit 1-1 shall be amended and replaced in its entirety
                                                            with Exhibit 1-2, attached hereto and incorporated herein by
                                                            this reference

 

		4.	Except as amended herein, all other terms and conditions of the Agreement shall remain in full force and effect.

 

		5.	This Amendment 3 may be executed in counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding
to the same extent as an original signature page.

 

[Signature page follows]

  

    	CONFIDENTIAL	Amendment No. 3 – Research and License Agreement	 

    	 

    

 

In
witness whereof, the Parties hereby accept and agree to the terms and conditions of this Amendment as of the Amendment 3
Effective Date.

 

	DEBIOPHARM S.A.	 	MARINA BIOTECH, INC.
	 	 	 
	By:	/s/ Mauvernay	 	By:	/s/ Peter S. Garcia
	 	 	 	 	 
	Name:	Mauvernay	 	Name:	Peter S. Garcia
	 	 	 	 	 
	Title:	President	 	Title:	CFO
	 	 	 	 	 
	 	 	 	 	

  

    	CONFIDENTIAL	Amendment No. 3 – Research and License Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]